Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound.
about
A functional CFTR assay using primary cystic fibrosis intestinal organoidsAdditive effect of multiple pharmacological chaperones on maturation of CFTR processing mutantsEnhancing the Potency of F508del Correction: A Multi-Layer Combinational Approach to Drug Discovery for Cystic Fibrosis.Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.Modulation of endocytic trafficking and apical stability of CFTR in primary human airway epithelial culturesNew horizons in the treatment of cystic fibrosis.Human equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations impair nucleoside transport, protein localization, and stability.Use of kinase inhibitors to correct ΔF508-CFTR function.Insulin-like growth factor 1 (IGF-1) enhances the protein expression of CFTR.A rapid membrane potential assay to monitor CFTR function and inhibition.Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain.Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTRCorrection of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.RNA Interference Screen to Identify Kinases That Suppress Rescue of ΔF508-CFTR.F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.Rhodamine inhibitors of P-glycoprotein: an amide/thioamide "switch" for ATPase activity.Insight in eukaryotic ABC transporter function by mutation analysis.Update in cystic fibrosis 2005Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small moleculesChemical and pharmacological chaperones as new therapeutic agents.Chemical and biological folding contribute to temperature-sensitive DeltaF508 CFTR traffickingFunctional Rescue of F508del-CFTR Using Small Molecule CorrectorsDefects in the leptin axis reduce abundance of the ABCG5-ABCG8 sterol transporter in liver.Cysteines introduced into extracellular loops 1 and 4 of human P-glycoprotein that are close only in the open conformation spontaneously form a disulfide bond that inhibits drug efflux and ATPase activity.Thiorhodamines containing amide and thioamide functionality as inhibitors of the ATP-binding cassette drug transporter P-glycoprotein (ABCB1).Cell surface rescue of kidney anion exchanger 1 mutants by disruption of chaperone interactions.High-content functional screen to identify proteins that correct F508del-CFTR function.Using a cysteine-less mutant to provide insight into the structure and mechanism of CFTR.Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket.The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants.Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines.Bithiazole correctors rescue CFTR mutants by two different mechanisms.Decreasing Poly(ADP-Ribose) Polymerase Activity Restores ΔF508 CFTR Trafficking.Synonymous codon usage affects the expression of wild type and F508del CFTR.Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.Pharmacological Chaperones: Potential for the Treatment of Hereditary Diseases Caused by Mutations in G Protein-Coupled Receptors
P2860
Q28291898-4F91BBF9-ADC5-471E-BAB2-F515B459CFC1Q33286071-74F49B04-F5B3-403B-A2A6-D704DE7187E5Q33632575-49567528-9CD5-4C28-A305-2750B06D99EBQ33717398-FC6EF1AA-16D0-469A-90EA-FC3673329225Q33728190-18CD7B3F-920E-4964-8504-26F36FAAAF53Q33756002-406265A4-D3C8-402B-85E4-91E8E7CAA644Q34107490-0F43FF4C-6ECB-4EA3-B1A3-B17607D416E6Q34304720-B5689984-6E95-4B97-909E-F09B295C89EFQ34652853-76CB2947-0499-49DC-8648-95B7326A9CBFQ34709811-1020248A-C3FC-4EA9-9A3F-BFB31E43C026Q34975364-6C3E8EFC-7FD9-4F33-9530-F3D9CEDA2445Q35107406-3AB9AF26-3DA8-4A1B-B4AB-4F0896339EFDQ35275697-A896708F-D5C6-47E1-9104-B1366FD6C845Q35558817-9F3C336F-761A-4BE0-97E3-AF3069822388Q35590787-E16FE0DE-C768-4688-B0DD-DA461056EDA7Q35630919-26E9BE76-F746-45CD-AB74-F206F43E4170Q36103906-98493EAC-4383-422C-ADC9-E2B696015352Q36379776-BE7C7856-90A4-4545-A900-ED1675886B4DQ36457176-500A00CC-162B-46DB-97B6-21C7093074F3Q36729796-75EDE120-29BD-4A34-B075-3AA024383151Q36863386-5554CFAE-CE70-42ED-BFA2-3F2C2AA5D4DBQ37196094-36222B70-6B2A-49D8-86F8-49E68F4822ADQ38051325-77F8F357-DBDF-45C8-8B02-802C1D131414Q38300931-8E61E04D-D480-407C-9165-EF9672B3321AQ38972586-7043E51F-EDC7-4552-8BB8-0D614BFFB708Q39326387-AAEE2497-0580-42A7-B15A-9444E4C9E8BFQ39680622-2D05C36B-4192-4C53-86E8-5AAA2ADCD0E3Q39904574-909BD11E-F1EC-44CF-9953-CE11B5863CD5Q40312181-8D7745EF-7E23-421D-9648-82119540F99FQ40313463-1C6B55A7-D5E0-4F42-98BD-6862596098DBQ40328635-C6271466-3575-4C8E-BB78-04CB12FF54B4Q41893111-60F8204A-0EA8-4E7F-AF8A-5A5BE99764FBQ42072189-755F8B4E-8E04-49D8-8AC1-AA01D81FF19CQ42324780-C7B563C9-F702-44F6-9A24-AB3048B39704Q42558062-553CCBD7-4C39-4F2C-BC74-0C2256FD3374Q50014672-B4C14AEA-2E86-4D6A-9827-6E2A2502AE2CQ51428010-03052C0B-9DA1-4DF6-BEAB-DF981C6032F2Q56648598-6994401C-EB5A-46CA-AE62-C78D76D4AE2E
P2860
Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound.
@en
type
label
Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound.
@en
prefLabel
Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound.
@en
P2093
P356
P1476
Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound.
@en
P2093
David M Clarke
M Claire Bartlett
P304
P356
10.1021/MP0500521
P407
P577
2005-09-01T00:00:00Z